Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 21,027 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Hypoxic-Ischemic Encephalopathy, Brain Ischemia Hypoxia
Interventions: Sulfur hexafluoride lipid-type A microspheres; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Minute to 18 Months
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Suicide, Mental Health Disorder, Anhedonia
Interventions: ViraBrite nudges; Behavioral
Lead sponsor: Ksana Health; Industry
Eligibility: 13 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Premenstrual Syndrome, Menstruation Disturbances
Interventions: Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcoholic Cirrhosis
Interventions: Placebo, SAMe 400 mg tablet; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Indianapolis, Indiana

Conditions: Knee Osteoarthritis
Interventions: Lorecivivint, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 69 more

Conditions: Hearing Loss, Sensorineural, Hearing Loss, Bilateral
Interventions: Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation; Device
Lead sponsor: Bruce J Gantz; Other
Eligibility: 12 Months to 24 Months
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Intermittent Hypoxia, Normoxia
Interventions: Intermittent Hypoxia, Normoxia (sham); Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Age Related Cognitive Decline
Interventions: PATH neurotraining, Orientation Discrimination; Behavioral
Lead sponsor: Perception Dynamics Institute; Industry
Eligibility: 55 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: La Jolla, California • Solana Beach, California

Conditions: Traumatic Brain Injury, Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Acute Anoxic Encephalopathy
Interventions: Indocyanine Green; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neuroblastoma, Relapsed Neuroblastoma, Recurrent Neuroblastoma, Osteosarcoma
Interventions: Ex vivo Expanded and Activated Haploidentical Donor NK Cells, Hu14.18-IL2; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Months to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Ovary Cancer
Interventions: EC1456, 99mTc-Etarfolatide; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Concord, North Carolina

Conditions: Restless Leg Syndrome
Interventions: RESTIFFIC™ Brand Pressure Application System; Device
Lead sponsor: Lake Erie Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Offensive Aggression, Sexual Aggression, Dating Violence Perpetration and Victimization
Interventions: Brief Motivational Interview; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 15 Years to 19 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dementia, Mixed, Dementia of Alzheimer Type, TBI (Traumatic Brain Injury)
Interventions: REACH Hope; Other
Lead sponsor: Memphis VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: Mobile, Alabama • Los Angeles, California • Pasadena, California + 11 more

Conditions: HIV, Risk Reduction Behavior
Interventions: InvestiDate, Non-Health Related Video Game; Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions: Amnion Injection, Betamethasone injection; Biological · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prediabetes
Interventions: Mindfulness-based diabetes prevention education group, Conventional diabetes prevention education group; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 25 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pediatric Recurrent Central Nervous System Tumors
Interventions: Personalized neoantigen DNA vaccine, Papivax Biotech TDS-IM v2.0, Peripheral blood draw; Biological · Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 25 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: S-2367 Placebo, S-2367 1600 mg q.d. 54 Weeks, S-2367 1600 mg q.d. 60 weeks, LCD (low calorie diet), RCD (reduced calorie diet); Drug · Other
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 842 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 37 more

Conditions: Pancreatic Adenocarcinoma
Interventions: PCX-12; Drug
Lead sponsor: Haoming (Carl) Qiu; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dietary Rice Bran Supplementation
Interventions: Vitamin A, Rice Bran + Vitamin A; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 4 Months to 10 Months
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Post Traumatic Stress Disorder
Interventions: Standard CPT, CPT-LEAP; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Jamaica Plain, Massachusetts

Conditions: Intellectual Disability, Variable
Interventions: Pre-Dental Telehealth (PDT); Behavioral
Lead sponsor: Boston University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

CEUS Evaluation of Hypoxic Ischemic Injury

Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

A Treatment Study for Premenstrual Syndrome (PMS)

SAMe Trial for Patients With Alcoholic Cirrhosis

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

Iowa/Nucleus 10/10 mm and Nucleus Freedom Feasibility Study

Intermittent Hypoxia and Balance Control

Improvements in Cognitive Skills of Older Adults Using Dynamic Visual Attention Training

Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome

A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration

REACH Hope Intervention for Dementia and TBI Caregivers

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

A Digital Intervention for HIV Prevention in Black Adolescent Girls

Amnion-Based Injections in the Shoulder

We Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

Pilot Feasibility of Rice Bran Supplementation in Children

Cognitive Processing Therapy for Posttraumatic Stress Disorder and Co-occurring Lived Experience Stress

A Pilot Project to Facilitate Dental Care and Reduce Barriers For Youth With Disabilities